Re:Search - Details

E5510: Inhibitor of platelet agregation

SUBMISSION ID 482

Contact Details

Provider Eisai Co., Ltd. - Eisai
Partnership Hub Coordinator Name BIO Ventures for Global Health
401 Terry Avenue North
Seattle, WA 98109
USA
Tel: +1 206 732 2122
info@bvgh.org

Submission Summary

TitleE5510: Inhibitor of platelet agregation
Executive Summary/Abstract E5510 inhibits platelet aggregation through inhibition of Prostaglandin H synthases and Phosphodiesterase.
Keywords PDE; cyclooxygenase; prostaglandin; platelet

Disease Selection

Disease Unknown
Comment
Name(s) of Infectious Organism(s)
Vector(s)
Human Target Organ(s)
Mechanism of Action (MoA)
Molecular or Cellular Target Name(s)

Type of Data

Type of Data Pre-Clinical Candidate










PRE-CLINICAL CANDIDATE DATA SUBFIELDS

Pre-Clinical Candidate Description

 
Strategy for selecting Pre-Clinical Candidate
Origin of Pre-Clinical Lead and Lead Series
How many Pre-Clinical Candidates have been Selected?
How many Pre-Clinical Candidates Abandoned?
Reason for Abandoning
How many Pre-Clinical Candidates Untouched?
Reason for Not Pursuing

Pre-Clinical Chemistry Description

 
Chemistry approach(es) to Pre-Clinical Candidate
Chemical structure(s) of Pre-Clinical Candidate
C125_E5510.pdf
SAR analysis summary
Scale-up synthesis route

Pre-Clinical Candidate Profile

 
Potency IC50=81 nM PGHS1 and 15.7 microM PDE 3
Off-target Activity
Animal Model/Data Description
In Vitro & In Vivo PK/PD
Solubility
Non-GMP/GMP Animal Tox and DMPK Data Summary
Safety Summary
Formulation
Other

Pre-Clinical Compound Availability

 
Quantity Produced in grams
Quantity Available in grams 0.01

Mechanism of Action (MoA)

 
Is the Mechanism of Action Known? No

Collaboration Status

 
In house only Yes

Publication/Patent Status

 
Proprietary Data Yes
Publicly Available Data (Reference)
Patented Data (Reference) Biol. Pharm. Bull. 19 6 , 828-833 1996 ; Japan. J. Pharmacol, 55, 81-91 1991 ; Japan. J. Pharmacol, 61, 7-12 1993